Categories: News

HPAPI 2020 Conference to Discuss Containment Solutions and ADC Developments

SMi reports: The Highly Potent Active Pharmaceutical Ingredients conference will explore real-world examples of PBD payload synthesis, manufacture of oncology products and design of ADC containment systems.

London, United Kingdom, February 12, 2020 –(PR.com)– On the 11th – 12th May 2020, industry professionals will convene in London to discuss the challenges of the HPAPI industry at the Highly Potent Active Pharmaceutical Ingredients conference.

The global market for Highly Potent Active Pharmaceutical Ingredients has experienced an increased growth, resulting from its major use in oncology for cancer treatment – more often in the form of antibody drug conjugates (ADC).

With this in mind, one of the underlying subjects of the conference will be on containment solutions and ADC developments, where real-world examples of PBD payload synthesis, manufacture of oncology products and design of ADC containment systems will be discussed in fine detail. The conference will feature three briefings dedicated to these topics from leading industry professionals:
1) CMC Strategies for the Timely Launch Preparation of Antibody-Drug-Conjugates as High Potent APIs
· The manufacture of highly potent ADCs – challenges and solutions
· Deciding when to outsource and when to keep in-house
· Bayer’s ADC production concept
· Best practices for CMO selection and outsourcing ADC development and manufacture
· The journey from development to launch – understanding the needs, solutions, risks and mitigations
Presented by Ulrich Ruemenapp, Head of Launch preparation and Coordination, Bayer Ag

2) Engineering in Support of ADC Containment – a Case Study
· Innovative solutions to dealing with increasing toxicity of ADCs
· Designing ADC containment systems
· The containment of ADCs – a case study from AZ
Presented by Peter Marshall, Associate Engineering Director, AstraZeneca

3) Manufacturing of Oncological Products: a Perspective by a CDMo
· New Product Introduction
· Cross Contamination Risk Assessment & Environmental Risk Assessment
· Case Study: ADC Manufacturing

Presented by Fabio Zenobi, EHS Director, BSP Pharmaceuticals

Interested parties can view the full agenda and register for the event online.

Highly Potent Active Pharmaceutical Ingredients
Main conference: 11th-12th May 2020
Post-conference workshop day: 13th May 2020
London, UK
Sponsored by: BSP Pharmaceuticals

Let’s block ads! (Why?)

Miscw.com

Recent Posts

FPT Software Partners with Ant Digital Technologies, Empowering Digital Economy

HANOI, Vietnam--(BUSINESS WIRE)--Global IT company FPT Software recently signed a Memorandum of Understanding (MoU) with…

1 hour ago

Mitsubishi Electric Subsidiary Joins Smart City Development Project at Former Berlin Tegel Airport

Will collaborate on piloting application of technologies to improve the energy efficiency, comfort and operational…

1 hour ago

FPT Software Collaborates with JAL Information Technology to Develop Strategic Aviation IT System

TOKYO--(BUSINESS WIRE)--#FPT--FPT Software signed a Memorandum of Understanding (MOU) with JAL Information Technology (JIT), a…

1 hour ago

REDEX to be an exclusive partner to TNBX in Malaysia to support the Malaysia Green Attribute Trading System (mGATS) platform

SINGAPORE - Media OutReach Newswire - 20 May 2024 - REDEX will be an exclusive…

2 hours ago

Swiss Re Foundation aims to boost health and environmental innovations through Shine Southeast Asia

Shine, Swiss Re Foundation's flagship social entrepreneurship programme, invites participation from social entrepreneurs from Indonesia,…

2 hours ago

Kirin Holdings will begin online sales of “Electric Salt Spoon”, a spoon that uses electricity to enhance salty and umami taste*1, on May 20

With this new business, Kirin aims to solve social issue of excessive salt intake. Spoons…

2 hours ago